Landsburg, Daniel J <br/><br/>
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.  [electronic resource] 

 -  Blood advances  01 2019 
 - 132-135 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2473-9537 
<br/><br/><label>Standard No.: </label>10.1182/bloodadvances.2018026401  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Biomarkers, Tumor<br/>Drug Resistance, Neoplasm<br/>Female<br/>Genes, bcl-2<br/>Genes, myc<br/>Humans<br/>Lymphoma, B-Cell--diagnosis<br/>Male<br/>Middle Aged<br/>Piperidines<br/>Prognosis<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyrazoles--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Recurrence<br/>Retreatment<br/>Treatment Outcome